Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RP-3500,Talazoparib
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for the treatment of solid tumors with selected genomic alterations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RP-3500
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 29, 2020
Details:
Repare intends to file an IND application in the 2Q20 for lead candidate,RP-3500, an oral small molecule inhibitor for the treatment of solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: $3,000.0 million Upfront Cash: $65.0 million
Deal Type: Collaboration May 26, 2020
Details:
Companies will leverage Repare’s proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx®, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
